This is a working overview of circadian clock, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-11-24. Anything still debated is marked as such rather than presented as settled.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule ligand; not a hormone or peptide |
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| CAS Registry Number | 1379686-30-2 | Unique chemical identifier |
| Common synonyms | SR9009; stenabolic | Stenabolic is informal and not an official name |
| Reported targets | REV-ERBα and REV-ERBβ | Nuclear receptors linked to circadian and metabolic regulation |
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
== History == The founding meeting for the CSCC was held in Montreal, Quebec on October 17, 1956. Since that time, the membership has grown to several hundred clinical chemists. In 1986 the Canadian Academy of Clinical Biochemistry was established as the academic body of the CSCC to oversee training, certification, accreditation, and professional development of clinical chemists in Canada. A syllabus for post doctoral training in clinical biochemistry was developed and is maintained by the CACB as a guide to program directors and trainees. The CSCC holds an Annual Scientific Congress and Annual General Meeting. The 61st annual CSCC conference was held in San Diego, CA, USA from July 31-August 4, 2017 as a joint meeting with the AACC.
== Use in antibody-drug conjugates == A new antibody-drug conjugate (ADC) technology based on α-amanitin has shown activity in therapy-resistant tumor cells, e.g. cells expressing multi-drug resistant transporters, tumor-initiating cells and non-dividing cells at picomolar concentrations. The unique mode of action of α-amanitin seems to make the amanitin-based ADCs a suitable toxic payload. This toxin has a water-soluble structure, resulting in ADCs with low tendency for aggregation. Significant clinical advances occurred in 2025 and 2026 with Heidelberg Pharma’s lead candidate HDP-101 (pamlectabart tismanitin), a BCMA-targeted amanitin-based antibody-drug conjugate (ATAC) for relapsed or refractory multiple myeloma. In the ongoing Phase I/IIa trial (NCT04879043), dose escalation proceeded safely up to 218 µg/kg without reaching a maximum tolerated dose, and the recommended Phase IIa dose was selected in April 2026. The program received FDA Fast Track designation in October 2025. In the higher-dose cohorts (90–140 µg/kg), overall response rates reached 38–57 %, with several heavily pretreated patients, including those who had failed prior BCMA-directed therapies, achieving stringent complete remissions lasting more than one year. The safety profile remained favorable, with mostly mild-to-moderate and manageable adverse events and no clinically relevant hepatotoxicity, ocular toxicity, or renal impairment.
== External links == "ETOH Database Search". hazelden.org. The National Institute on Alcohol Abuse and Alcoholism maintains a database of alcohol-related health effects. ETOH Archival Database (1972–2003) Alcohol and Alcohol Problems Science Database. "Harmful Interactions". National Institute on Alcohol Abuse and Alcoholism (NIAAA). WHO fact sheet on alcohol ChEBI – biology related Kyoto Encyclopedia of Genes and Genomes signal transduction pathway: KEGG – human alcohol addiction
Peukert ended his essay stating that there were debates about "our dealings with others, notably those different from ourselves. Recent debates about foreign migrants and AIDs present a conflicting picture. On one hand, we can see the continuing survival of a discourse on segregation, untouched by any historical self-consciousness. On the other hand, however, there is a considerable body of opinion pledging for tolerance and responsibility that spring from an awareness of German history and of the genesis of the "Final Solution" from the spirit of science".
Sources: en.wikipedia.org
The activities of progesterone besides those mediated by the PRs and mPRs are also of significance. Progesterone lowers blood pressure and reduces water and salt retention among other effects via its antimineralocorticoid activity. In addition, progesterone can produce sedative, hypnotic, anxiolytic, euphoric, amnestic, cognitive-impairing, motor-impairing, anticonvulsant, and even anesthetic effects via formation of sufficiently high concentrations of its neurosteroid metabolites and consequent GABAA receptor potentiation in the brain. There are differences between progesterones and progestins, such as medroxyprogesterone acetate and norethisterone, with implications for pharmacodynamics and pharmacokinetics, as well as for efficacy, tolerability, and safety.
Triple-stranded DNA has been observed in supercoiled Satellite DNA in regions where microsatellite copy numbers are highly variable, along with inverted-repeat Z-DNA structures within a larger 2.1kb satellite DNA repeat unit.
Cohen, M. Michael; Howell, Robin E. (October 1999). "Etiology of fibrous dysplasia and McCune–Albright syndrome". International Journal of Oral and Maxillofacial Surgery. 28 (5): 366–371. doi:10.1016/s0901-5027(99)80085-x. PMID 10535539.
Sources: en.wikipedia.org
Histologically, an excess amount of keratin is noted on the surface of the tissue, and the tissue has all the layers of an orthokeratinized tissue with its granular and keratin layers. In patients who have habits such as clenching or grinding (bruxism) their teeth, a larger area of the buccal mucosa than just the linea alba becomes hyperkeratinized. This larger white, rough, raised lesion needs to be recorded so that changes may be made in the dental treatment plan regarding the patient's parafunctional habits. Even keratinized tissue can undergo further level of hyperkeratinization; an increase in the amount of keratin is produced as a result of chronic physical trauma to the region. Changes such as hyperkeratinization are reversible if the source of the injury is removed, but it takes time for the keratin to be shed or lost by the tissue. Thus, to check for malignant changes, a baseline biopsy and microscopic study of any whitened tissue may be indicated, especially if in a high-risk cancer category, such with a history of tobacco or alcohol use or are HPV positive. Hyperkeratinized tissue is also associated with the heat from smoking or hot fluids on the hard palate in the form of nicotinic stomatitis. The lamina propria is a fibrous connective tissue layer that consists of a network of type I and III collagen and elastin fibers in some regions. The main cells of the lamina propria are the fibroblasts, which are responsible for the production of the fibers as well as the extracellular matrix.
== Thermodynamics == At constant temperature and pressure, one must consider the Gibbs free energy, G, while at constant temperature and volume, one must consider the Helmholtz free energy, A, for the reaction; and at constant internal energy and volume, one must consider the entropy, S, for the reaction. The constant volume case is important in geochemistry and atmospheric chemistry where pressure variations are significant. Note that, if reactants and products were in standard state (completely pure), then there would be no reversibility and no equilibrium. Indeed, they would necessarily occupy disjoint volumes of space. The mixing of the products and reactants contributes a large entropy increase (known as entropy of mixing) to states containing equal mixture of products and reactants and gives rise to a distinctive minimum in the Gibbs energy as a function of the extent of reaction. The standard Gibbs energy change, together with the Gibbs energy of mixing, determine the equilibrium state. In this article only the constant pressure case is considered. The relation between the Gibbs free energy and the equilibrium constant can be found by considering chemical potentials. At constant temperature and pressure in the absence of an applied voltage, the Gibbs free energy, G, for the reaction depends only on the extent of reaction: ξ (Greek letter xi), and can only decrease according to the second law of thermodynamics. It means that the derivative of G with respect to ξ must be negative if the reaction happens; at the equilibrium this derivative is equal to zero.
After non-avian dinosaurs were discovered, paleontologists first posited that they were ectothermic. This was used to imply that the ancient dinosaurs were relatively slow, sluggish organisms, even though many modern reptiles are fast and light-footed despite relying on external sources of heat to regulate their body temperature. The idea of dinosaurs as ectothermic remained a prevalent view until Robert T. Bakker, an early proponent of dinosaur endothermy, published an influential paper on the topic in 1968. Bakker specifically used anatomical and ecological evidence to argue that sauropods, which had hitherto been depicted as sprawling aquatic animals with their tails dragging on the ground, were endotherms that lived vigorous, terrestrial lives. In 1972, Bakker expanded on his arguments based on energy requirements and predator-prey ratios. This was one of the seminal results that led to the dinosaur renaissance. One of the greatest contributions to the modern understanding of dinosaur physiology has been paleohistology, the study of microscopic tissue structure in dinosaurs. From the 1960s forward, Armand de Ricqlès suggested that the presence of fibrolamellar bone—bony tissue with an irregular, fibrous texture and filled with blood vessels—was indicative of consistently fast growth and therefore endothermy. Fibrolamellar bone was common in both dinosaurs and pterosaurs, though not universally present.
However, the result of the fight was overturned to a No Contest and Casey was suspended for three months by the Texas Department of Licensing and Regulation after an in-competition sample provided by Casey was found to have an elevated testosterone to epi-testosterone ratio. Several experts questioned the findings and in June 2017 she was exonerated by the UFC after follow up testing showed no evidence of doping. On June 29 the UFC issued a strongly worded statement requesting that "the Texas Department of Licensing and Regulation (TDLR) immediately reverse its ruling and exonerate Cortney of any wrongdoing". In turn, on June 30, the TDLR lifted Casey's three-month suspension and reinstated her victory. Casey faced Felice Herrig on December 2, 2017 at UFC 218. She lost the bout via split decision. Casey fought against Michelle Waterson at UFC on Fox 29 in Glendale, AZ on April 14. Cortney lost the fight via split decision Casey faced Angela Hill on August 25, 2018 at UFC Fight Night 135. She won the fight via split decision. Casey next faced Cynthia Calvillo on February 17, 2019 at UFC on ESPN 1. She lost the fight by unanimous decision. Casey was expected to face Virna Jandiroba on December 7, 2019 at UFC on ESPN 7. However, Casey withdrew from the event for an undisclosed reason and she was replaced by Lívia Renata Souza Casey was scheduled to face Lara Procópio on May 16, 2020 at UFC Fight Night 175 (San Diego).
Sources: en.wikipedia.org
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.
No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.
Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.